About the Study Medication

What is the study medication?

The investigational study medication, AR1001, consists of 2 pills that you take each morning before breakfast. It is designed to help brain cells grow, repair themselves, and communicate. This may slow or reverse early signs of Alzheimer’s disease and mild cognitive impairment progression.

The study drug has been tested in humans and appears to be well tolerated. However, it is not an approved early Alzheimer’s treatment. Therefore, it is considered investigational and can only be used in research.

Will I receive the study medication?

• If you qualify, you will be assigned by chance to receive either the study drug or a placebo (no active ingredient).
• Neither you nor the study staff will know which you are receiving.
• You have a 50% chance of receiving the study drug during the first year of the trial. During the 2-year extension phase, all study participants will receive the study drug.

What is an investigational drug?

Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like POLARIS-AD.